carbamazepine and lamotrigine

Carbamazepine induces hepatic uridine diphosphate glucuronosyltransferase (UGT) enzymes, particularly UGT1A4, which is the primary enzyme responsible for lamotrigine metabolism. This induction increases the clearance and reduces the plasma concentration of lamotrigine. The effect is dose dependent and develops over several weeks of carbamazepine therapy.

Patients may experience subtherapeutic lamotrigine concentrations, leading to reduced efficacy, such as breakthrough seizures or worsening of mood symptoms in bipolar disorder. When carbamazepine is withdrawn, lamotrigine concentrations can rise substantially, increasing the risk of toxicity including dizziness, ataxia, nystagmus, and diplopia. This interaction is clinically relevant and can have serious consequences if not managed.

Monitor lamotrigine plasma concentrations and clinical response when carbamazepine is initiated, adjusted, or discontinued. Increase the lamotrigine dose when carbamazepine is added, and decrease it when carbamazepine is stopped. Dose adjustments should be based on therapeutic drug monitoring and the patient's clinical status. Follow local prescribing guidelines and specialist advice.

Well established through clinical pharmacokinetic studies and practical experience. Carbamazepine is a potent enzyme inducer, and its effect on lamotrigine metabolism is predictable. The interaction is documented in standard drug interaction references and product information.